Compare ENPH & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENPH | RYTM |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | 2872 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.8B |
| IPO Year | 2011 | 2017 |
| Metric | ENPH | RYTM |
|---|---|---|
| Price | $45.14 | $109.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 23 | 14 |
| Target Price | $41.30 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 6.4M | 985.9K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.00 | 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,985,000.00 | N/A |
| Revenue This Year | N/A | $55.34 |
| Revenue Next Year | $9.81 | $86.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.72 | N/A |
| 52 Week Low | $25.78 | $74.50 |
| 52 Week High | $73.74 | $122.20 |
| Indicator | ENPH | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 60.84 |
| Support Level | $41.24 | $98.30 |
| Resistance Level | $46.87 | $113.03 |
| Average True Range (ATR) | 3.66 | 4.86 |
| MACD | -0.53 | 0.24 |
| Stochastic Oscillator | 29.38 | 63.85 |
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.